Loading clinical trials...
Loading clinical trials...
A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency
Conditions
Interventions
AG-348
Locations
13
United States
Stanford University
Palo Alto, California, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Wayne State University School of Medicine - Children's Hospital of Michigan
Detroit, Michigan, United States
New York Presbyterian Hospital- Weil Cornell Medical College
New York, New York, United States
Central Pennsylvania Clinic
Belleville, Pennsylvania, United States
Children Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania, United States
Start Date
June 26, 2015
Primary Completion Date
May 8, 2017
Completion Date
April 2, 2025
Last Updated
May 2, 2025
NCT05144256
NCT03481738
NCT06422351
NCT04995315
NCT04964323
NCT03866590
Lead Sponsor
Agios Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions